Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Stock Performance and Regulatory Issues - On January 15, 2026, Disc Medicine faced a stock price decline of $6.04 per share, or 7.84%, closing at $71.04 per share due to a delay in the review timeline of a drug after the FDA raised safety and efficacy concerns [3]. - On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its New Drug Application for bitopertin, leading to a significant stock price drop of $15.70 per share, or 21.91%, closing at $55.95 per share [4][5].

Core Viewpoint - Disc Medicine, Inc. is under investigation for potential violations of federal securities laws following the FDA's issuance of a Complete Response Letter (CRL) for its lead therapeutic candidate, bitopertin, which delays approval and impacts the company's valuation significantly [1][2][5]. Group 1: FDA Response and Impact - On February 13, 2026, the FDA issued a CRL for bitopertin, indicating that the application cannot be approved in its current form and requires additional data submissions [2]. - Bitopertin was positioned as a transformative therapy for approximately 4,000 Erythropoietic protoporphyria (EPP) patients in the U.S., and the CRL delays potential approval until at least 2027, eliminating near-term commercial revenue [3]. - Following the CRL announcement, Disc shares declined by 21.9%, reflecting the market's prior expectations of a favorable FDA outcome based on the company's communications [4]. Group 2: Investigation Focus - The investigation by Levi & Korsinsky is centered on whether Disc and its senior executives made statements regarding the regulatory prospects of bitopertin that did not fully disclose the risks and challenges faced in interactions with the FDA prior to the CRL [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket fees or costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, indicating that the new drug application could not be approved due to uncertainties requiring additional evidence [3]. - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Disc Medicine, Inc. has completed enrollment in the Phase 3 APOLLO trial for bitopertin, which targets erythropoietic protoporphyria (EPP), expanding the study size to 183 participants due to high demand [1][7]. Group 1: Study Details - The APOLLO trial is a double-blind, placebo-controlled study involving patients aged 12 and above, with sites in the US, Canada, Europe, and Australia [2]. - Co-primary endpoints include average monthly total time in sunlight without pain and percent change in whole blood metal-free PPIX after 6 months of treatment [2]. - Results from the APOLLO study are expected in Q4 2026, with a complete response letter (CRL) to be submitted to the FDA, and a decision anticipated by mid-2027 [2][7]. Group 2: About Bitopertin - Bitopertin is an investigational, orally administered inhibitor of glycine transporter 1 (GlyT1), aimed at modulating heme biosynthesis and supporting erythropoiesis [3]. - It is being developed as a potential first disease-modifying therapy for erythropoietic porphyrias [3]. - The drug has undergone multiple clinical trials, including the Phase 2 BEACON and AURORA trials, and the ongoing Phase 3 APOLLO trial [3]. Group 3: Company Overview - Disc Medicine is focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases, targeting heme biosynthesis and iron homeostasis [5]. - The company aims to build a portfolio of innovative therapeutic candidates to address a wide spectrum of hematologic diseases [5]. - Disc obtained global rights to bitopertin from Roche in May 2021 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a class action without any out-of-pocket fees or costs [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3]. - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Developments - On January 15, 2026, Disc Medicine faced a delay in the review timeline of a drug under development due to safety and efficacy concerns raised by the U.S. Food and Drug Administration (FDA), resulting in a stock price drop of $6.04 per share, or 7.84%, closing at $71.04 per share [3] - On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for bitopertin, indicating that clinical trials did not demonstrate a significant association between percent change in PPIX and sunlight exposure-based endpoints, leading to a further stock price decline of $15.70 per share, or 21.91%, closing at $55.95 per share [4][5] Group 2: Legal and Investigative Actions - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is conducting an investigation on behalf of investors of Disc Medicine, focusing on potential securities fraud and other unlawful practices [1][6]

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3]. - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - Investors are encouraged to join the prospective class action by contacting Rosen Law Firm for more information [2] Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3] - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their experience and recognition in the field [4] - The firm has achieved notable settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Accessibility StatementSkip NavigationNEW YORK, March 20, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.So W ...